Quick Takeaways
- Southpoint Capital Advisors LP filed SCHEDULE 13G/A for Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC).
- Disclosed ownership: 8%.
- Date of event: 31 Dec 2025.
Quoteable Key Fact
"Southpoint Capital Advisors LP disclosed 8% ownership in Fennec Pharmaceuticals Inc. Common Shares, no par value (FENC) on 31 Dec 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Southpoint Master Fund, LP | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | By Southpoint GP, LP, its General Partner, by Southpoint GP LLC, its General Partner, by John S. Clark II, Managing Member | |
| Southpoint Capital Advisors LP | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | By Southpoint Capital Advisors LLC, its General Partner, by John S. Clark II, Managing Member | |
| Southpoint Capital Advisors LLC | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | John S. Clark II, Managing Member | |
| Southpoint GP, LP | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | John S. Clark II, Managing Member | |
| Southpoint GP, LLC | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | John S. Clark II, Managing Member | |
| John S. Clark II | 8% | 2,744,741 | 0 | 2,744,741 | /s/ John S. Clark II | John S. Clark II, individually |